An interventional study of CoreMap EP Mapping System Mapping and CoreMap EP Mapping System Map-Guided Ablation in Persistent Atrial Fibrillation, sponsored by CoreMap Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by CoreMap Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 235th largest by planned enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 405 with no phase, reaches primary completion later than 67 of the 219 other live ones, and was the 892nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 40+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 54 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 245 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with CoreMap Inc. as lead sponsor.
CoreMap Inc. has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
75 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 75 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global, multi-site, prospective, feasibility study.
The INvENI Study consists of three phases:
Phase 1, the goal is to collect and analyze high fidelity endocardial electrograms (EGMs) in patients with persistent AF (PerAF) and long-standing persistent AF and to demonstrate safety.
Phase 2, the goal is the initial development and evaluation of a CoreMap-guided tailored ablation strategy and to demonstrate safety and effectiveness of the CoreMap EP Mapping System in patients with PerAF and long-standing persistent AF.
Phase 3, the goal is to evaluate the safety and effectiveness of the CoreMap EP Mapping System's ability to identify spatially constrained AF drivers and guide ablation therapy in PerAF patients with no history of prior AF ablation. This phase aims to demonstrate safety and effectiveness compared to a control arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following within three months of enrollment:
Any of the following within six months of enrollment:
Any of the following cardiac conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For Phase 1, the goal is to collect and analyze high fidelity endocardial electrograms (EGMs) in patients with persistent AF (PerAF) and long-standing persistent AF and to demonstrate safety.
Device: CoreMap EP Mapping System Mapping
The Phase 2 goal is the initial development and evaluation of a CoreMap-guided tailored ablation strategy and to demonstrate safety and effectiveness of the CoreMap EP Mapping System in patients with PerAF and long-standing persistent AF..
Device: CoreMap EP Mapping System Mapping · Device: CoreMap EP Mapping System Map-Guided Ablation
For Phase 3, the goal is to evaluate the safety and effectiveness of the CoreMap EP Mapping System's ability to identify spatially constrained AF drivers and guide ablation therapy in PerAF patients with no history of prior AF ablation therapy. This phase aims to demonstrate safety and effectiveness compared to a control arm.
Device: CoreMap EP Mapping System Mapping · Device: CoreMap EP Mapping System Map-Guided Ablation
Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.
Phases 1 and Phase 2 Primary Endpoint:
Incidence of study device related serious adverse events within seven (7) days of the study procedure.
Time frame: 7 days
Phase 2 and Phase 3 Primary Effectiveness Endpoint:
Freedom from documented recurrence of AF, atrial tachycardia (AT), or atrial flutter (AFL) based on electrocardiographic data through a 12-month follow-up and excluding a 90-day blanking period.
Time frame: 6 and 12 months
Phase 1 Secondary Endpoint:
Successful completion of the intended study mapping procedure with the CoreMap EP Mapping System.
Time frame: perioperatively/periprocedurally
Phase 2 Secondary Endpoints:
AF rhythm change or termination following CoreMap-guided ablation.
Time frame: perioperatively/periprocedurally
Phase 3 Secondary Endpoints:
AF rhythm change or termination following CoreMap-guided ablation vs. PVI+PW ablation of control arm.
Time frame: perioperatively/periprocedurally
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 29 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.